Kazia Therapeutics' (KZIA) shares jumped 55% in recent Thursday trading after the company announced the regulatory approval and launch of a clinical trial evaluating the combination of its investigational drug paxalisib and immunotherapy in patients with advanced breast cancer.
The multi-center, open-label phase 1b study will assess the safety and efficacy of paxalisib combined with Merck's (MRK) Keytruda or Lynparza in women with triple-negative breast cancer, Sydney-based Kazia said Thursday in a statement.
The study will enroll 24 patients from cancer centers in Queensland with treatment lasting up to 12 months, the company said.
The trial also will evaluate a non-invasive liquid biopsy digital pathology platform, developed by scientists at the QIMR Berghofer Medical Research Institute, to monitor treatment progress in real time, through blood sample analysis, the company said.
Merck shares rose 0.5% in recent Thursday trading.
Price: 2.14, Change: +0.76, Percent Change: +54.79
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。